Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Novartis
Kivu Bioscience Inc.
BeOne Medicines
Aktis Oncology, Inc.
Exelixis
Eli Lilly and Company
Arcus Biosciences, Inc.
Radiopharm Theranostics, Ltd
Seagen Inc.
Bayer
IntoCell, Inc
Tizona Therapeutics, Inc
Eli Lilly and Company
NiKang Therapeutics, Inc.
SystImmune Inc.
City of Hope Medical Center
Boundless Bio, Inc.
Eli Lilly and Company
Novartis
Eli Lilly and Company
Seagen Inc.
Innate Pharma
Novartis
Compass Therapeutics
NeoTX Therapeutics Ltd.
Bolt Biotherapeutics, Inc.
AbbVie
Nanobiotix
Rondo Therapeutics
Daiichi Sankyo
Hummingbird Bioscience
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
NiKang Therapeutics, Inc.
Nurix Therapeutics, Inc.
Valo Therapeutics Oy
Memgen, Inc.
Exelixis
AbbVie
Xencor, Inc.
Incyte Corporation
Genentech, Inc.
Lyell Immunopharma, Inc.
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Theratechnologies